These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 34506909)
1. Perfusion parameters derived from MRI for preoperative prediction of IDH mutation and MGMT promoter methylation status in glioblastomas. Lu J; Li X; Li H Magn Reson Imaging; 2021 Nov; 83():189-195. PubMed ID: 34506909 [TBL] [Abstract][Full Text] [Related]
2. Arterial spin labeling perfusion-weighted imaging aids in prediction of molecular biomarkers and survival in glioblastomas. Yoo RE; Yun TJ; Hwang I; Hong EK; Kang KM; Choi SH; Park CK; Won JK; Kim JH; Sohn CH Eur Radiol; 2020 Feb; 30(2):1202-1211. PubMed ID: 31468161 [TBL] [Abstract][Full Text] [Related]
3. Choi HJ; Choi SH; You SH; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH; Park CK; Park SH AJNR Am J Neuroradiol; 2021 May; 42(5):853-860. PubMed ID: 33632732 [TBL] [Abstract][Full Text] [Related]
5. Non-invasive prediction of p53 and Ki-67 labelling indices and O-6-methylguanine-DNA methyltransferase promoter methylation status in adult patients with isocitrate dehydrogenase wild-type glioblastomas using diffusion-weighted imaging and dynamic susceptibility contrast-enhanced perfusion-weighted imaging combined with conventional MRI. Xing Z; Huang W; Su Y; Yang X; Zhou X; Cao D Clin Radiol; 2022 Aug; 77(8):e576-e584. PubMed ID: 35469666 [TBL] [Abstract][Full Text] [Related]
6. Assessing the predictability of IDH mutation and MGMT methylation status in glioma patients using relaxation-compensated multipool CEST MRI at 7.0 T. Paech D; Windschuh J; Oberhollenzer J; Dreher C; Sahm F; Meissner JE; Goerke S; Schuenke P; Zaiss M; Regnery S; Bickelhaupt S; Bäumer P; Bendszus M; Wick W; Unterberg A; Bachert P; Ladd ME; Schlemmer HP; Radbruch A Neuro Oncol; 2018 Nov; 20(12):1661-1671. PubMed ID: 29733378 [TBL] [Abstract][Full Text] [Related]
7. Predictive value of MGMT promoter methylation on the survival of TMZ treated Chai R; Li G; Liu Y; Zhang K; Zhao Z; Wu F; Chang Y; Pang B; Li J; Li Y; Jiang T; Wang Y Cancer Biol Med; 2021 Feb; 18(1):272-282. PubMed ID: 33628600 [TBL] [Abstract][Full Text] [Related]
8. Different diagnostic values of imaging parameters to predict pseudoprogression in glioblastoma subgroups stratified by MGMT promoter methylation. Yoon RG; Kim HS; Paik W; Shim WH; Kim SJ; Kim JH Eur Radiol; 2017 Jan; 27(1):255-266. PubMed ID: 27048531 [TBL] [Abstract][Full Text] [Related]
9. The association between Okita Y; Shofuda T; Kanematsu D; Yoshioka E; Kodama Y; Mano M; Kinoshita M; Nonaka M; Fujinaka T; Kanemura Y Clin Radiol; 2020 Aug; 75(8):622-628. PubMed ID: 32321646 [TBL] [Abstract][Full Text] [Related]
10. Relationship between molecular characteristics of glioblastoma multiforme and the subventricular zone. Ashraf M; Abdelsadg M; Grivas A Br J Neurosurg; 2024 Oct; 38(5):1100-1107. PubMed ID: 35038937 [TBL] [Abstract][Full Text] [Related]
11. Prediction of Ki-67 labeling index, ATRX mutation, and MGMT promoter methylation status in IDH-mutant astrocytoma by morphological MRI, SWI, DWI, and DSC-PWI. Yang X; Hu C; Xing Z; Lin Y; Su Y; Wang X; Cao D Eur Radiol; 2023 Oct; 33(10):7003-7014. PubMed ID: 37133522 [TBL] [Abstract][Full Text] [Related]
12. MGMT Promoter Methylation Status Is Not Related to Histological or Radiological Features in IDH Wild-type Glioblastomas. Mikkelsen VE; Dai HY; Stensjøen AL; Berntsen EM; Salvesen Ø; Solheim O; Torp SH J Neuropathol Exp Neurol; 2020 Aug; 79(8):855-862. PubMed ID: 32688383 [TBL] [Abstract][Full Text] [Related]
13. Predicting MGMT Promoter Methylation of Glioblastoma from Dynamic Susceptibility Contrast Perfusion: A Radiomic Approach. Crisi G; Filice S J Neuroimaging; 2020 Jul; 30(4):458-462. PubMed ID: 32374045 [TBL] [Abstract][Full Text] [Related]
14. Discriminating MGMT promoter methylation status in patients with glioblastoma employing amide proton transfer-weighted MRI metrics. Jiang S; Rui Q; Wang Y; Heo HY; Zou T; Yu H; Zhang Y; Wang X; Du Y; Wen X; Chen F; Wang J; Eberhart CG; Zhou J; Wen Z Eur Radiol; 2018 May; 28(5):2115-2123. PubMed ID: 29234914 [TBL] [Abstract][Full Text] [Related]
15. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy. Li H; Li J; Cheng G; Zhang J; Li X Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705 [TBL] [Abstract][Full Text] [Related]
16. The interplay mechanism between IDH mutation, MGMT-promoter methylation, and PRMT5 activity in the progression of grade 4 astrocytoma: unraveling the complex triad theory. Kurdi M; Alkhotani A; Sabbagh A; Faizo E; Lary AI; Bamaga AK; Almansouri M; Hafiz B; Alsharif T; Baeesa S Oncol Res; 2024; 32(6):1037-1045. PubMed ID: 38827324 [TBL] [Abstract][Full Text] [Related]
17. The TERT promoter mutation status and MGMT promoter methylation status, combined with dichotomized MRI-derived and clinical features, predict adult primary glioblastoma survival. Shu C; Wang Q; Yan X; Wang J Cancer Med; 2018 Aug; 7(8):3704-3712. PubMed ID: 29984907 [TBL] [Abstract][Full Text] [Related]
19. Structural and advanced imaging in predicting MGMT promoter methylation of primary glioblastoma: a region of interest based analysis. Han Y; Yan LF; Wang XB; Sun YZ; Zhang X; Liu ZC; Nan HY; Hu YC; Yang Y; Zhang J; Yu Y; Sun Q; Tian Q; Hu B; Xiao G; Wang W; Cui GB BMC Cancer; 2018 Feb; 18(1):215. PubMed ID: 29467012 [TBL] [Abstract][Full Text] [Related]
20. Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation. Kessler T; Sahm F; Sadik A; Stichel D; Hertenstein A; Reifenberger G; Zacher A; Sabel M; Tabatabai G; Steinbach J; Sure U; Krex D; Grosu AL; Bewerunge-Hudler M; Jones D; Pfister SM; Weller M; Opitz C; Bendszus M; von Deimling A; Platten M; Wick W Neuro Oncol; 2018 Feb; 20(3):367-379. PubMed ID: 29016808 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]